In individuals with NC, metformin use was linked to improved memory performance over time, while in those with AD, DPP‐4i use was associated with a slower rate of memory decline. Additionally, interaction analyses indicated that the cognitive benefits of DPP‐4 inhibitors were more pronounced in APOE ε4 carriers. Here, APOE is linked to Alzheimer disease.